AIDX.TO Healwell AI Inc. (TSX) C$0.90 Pre-Market Mar 10 2026: Earnings catalyst ahead

AIDX.TO stock trades at C$0.90 in pre-market action on 10 Mar 2026 as investors position ahead of fiscal Q4 results. The company reports on Mar 19, 2026, with a conference call on Mar 20 that can drive volume and price swings. Healwell AI Inc. (AIDX.TO) shows volume 702,538 and average volume 563,642, signaling active interest. We examine valuation, technicals, catalysts and Meyka AI’s model forecast for Canadian investors and short-term traders.

AIDX.TO stock: Pre-market price, volume and short-term setup

Healwell AI Inc. (AIDX.TO) opened at C$0.94 and sits at C$0.90, down 5.26% on the session with a day range of C$0.85–C$0.94. The stock shows volume 702,538 versus average volume 563,642, a relative volume of 1.25, which points to above-average trading ahead of earnings.

One immediate trading fact: the 50-day average is C$0.79 and the 200-day average is C$1.17, so the stock is above its short-term average but below the longer-term mean. That mixed placement often precedes volatility around corporate news.

Earnings catalyst and company update

Healwell AI will release fourth-quarter and full-year 2025 results on Mar 19, 2026 with a conference call on Mar 20 at 8:30 AM ET. Management expects to discuss revenue drivers for AI clinical decision support and the strategic alliance with WELL Health Technologies, both material to near-term guidance Newsfile.

Investors should watch organic revenue, margins and cash flow trends. Current guidance is unknown publicly, so the report can meaningfully move the stock, especially given the company’s negative EPS of -C$0.23 and trailing PE -3.91.

Fundamentals and valuation for AIDX.TO stock

Healwell AI’s market cap is C$250,557,985 with 278,397,768 shares outstanding. Key metrics show revenue per share C$0.42, book value per share C$0.52, and cash per share C$0.07, underscoring a small-cap balance sheet with limited cash cushion.

Valuation multiples are mixed. Price-to-sales is 2.50, price-to-book is 1.78, and EV-to-sales is 3.23. Profitability remains weak: operating margin -106.49% and return on equity -56.89%, which frames a high-risk, development-stage healthcare AI name in the Canadian market.

Technical picture and trading signals

Technicals show short-term strength but overbought momentum. RSI is 72.36 and CCI is 168.25, both in overbought territory. MACD histogram turned positive (MACD 0.02, signal -0.02), suggesting momentum is leaning up despite the session decline.

Volatility measures are notable: ATR C$0.07 and Bollinger Bands range C$0.52–C$0.89. Traders should expect wide intraday swings. Use tight risk management given the stock’s small market cap and thin liquidity compared with large healthcare names.

Meyka AI grade and AIDX.TO stock forecast

Meyka AI rates AIDX.TO with a score out of 100: 62.24 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are model outputs and are not personal financial advice.

Meyka AI’s forecast model projects a quarterly price of C$0.72 and a monthly figure of C$0.65, versus the current C$0.90. The model-based quarterly projection implies an implied downside of -20.00% from the current price. Forecasts are model-based projections and not guarantees.

Risks and opportunities for investors

Opportunity: Healwell’s AI clinical decision tools and the WELL Health alliance can expand commercial reach if revenue growth accelerates. Historical growth metrics show revenue growth 4.33% year-over-year and gross profit growth 12.77%, suggesting operational progress.

Risk: negative operating cash flow per share -C$0.10, current ratio 0.85, and net losses leave the company exposed to capital needs. The company’s external rating recently showed D+ (Strong Sell) on fundamentals, which is a cautionary flag for conservative investors Seeking Alpha.

Final Thoughts

Key takeaways for AIDX.TO stock: Healwell AI trades at C$0.90 pre-market on Mar 10 2026 with above-average volume ahead of Q4 results on Mar 19. Fundamentals show early-stage revenue growth but negative profitability and constrained liquidity. Technically, momentum is strong but overbought, which raises the chance of a pullback on any weak guidance. Meyka AI’s forecast model projects a quarterly level of C$0.72, implying a -20.00% downside versus the current price. For scenario planning we offer three illustrative price targets: Bear C$0.60 (-33.33%), Base C$0.80 (-11.11%), Bull C$1.40 (+55.56%). These targets reflect the company’s year range (low C$0.58, high C$1.81) and current risk profile. Use the Mar 19 results and Mar 20 call to update positions; traders may use tight stops, while longer-term investors should monitor cash flow improvement and commercial traction. Meyka AI is an AI-powered market analysis platform and these views combine model outputs with market facts. Forecasts and grades are model-based projections and not guarantees or investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.